Press Releases Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Delayed Japan Exchange Other stock markets 01:22:46 15/05/2024 BST			5-day change	1st Jan Change
70 ^JPY	-1.41%		-10.26%	-43.55%

05-07	Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	CI
04-30	Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)	05-07	BU
Modalis Announces updated strategic plan and business consolidation of US operation	04-15	AQ
Modalis Announces Partnership with Ginkgo Bioworks	04-15	AQ
Modalis Announces Partnership with Ginkgo Bioworks	04-12	BU
Modalis and JCR Pharmaceuticals enter into joint research agreement	12-12	BU
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting	19/04/23	BU
Modalis Therapeutics : Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)	05/07/22	PU
Modalis Therapeutics : Notice Regarding a Patent Allowance for ‘Method for treating muscular dystrophy by targeting utrophin gene’ in the USA	22/06/22	PU
Modalis Therapeutics : Notice Regarding of Issuance of Stock Options (Share Acquisition Rights)	15/06/22	PU
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other Genetic Disorders at the ASGCT Annual Meeting	20/04/22	BU
Modalis Therapeutics : to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines at the ASGCT Annual Meeting	20/04/22	PU
Modalis Therapeutics : Notice Regarding of Issuance of Stock Options (Share Acquisition Rights)	15/04/22	PU
Modalis Therapeutics : Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)	15/04/22	PU
Modalis Therapeutics : Business Plans and Matters Related to High Growth Potential	29/03/22	PU
Modalis Therapeutics : Announcement of Issuance of Stock Options (Share Acquisition Rights)	29/03/22	PU
Modalis Therapeutics : Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus	22/02/22	PU
Modalis Therapeutics : Announces Termination of Research Collaboration on MDL-204	07/01/22	PU
Modalis Therapeutics : Q＆A regarding Notice of Modalis Announces Termination of a Research Collaboration on MDL-204	07/01/22	PU
Modalis Therapeutics : Business Plans and Matters Related to High Growth Potential	15/11/21	PU
Consolidated Financial Results for the Nine Months Ended September 30, 2021[Japanese GAAP]	05/11/21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Press Releases

Filters